Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "LIBERTY"

7 News Found

Microbot Medical begins full US market release of LIBERTY endovascular robotic system
Medical Device | April 15, 2026

Microbot Medical begins full US market release of LIBERTY endovascular robotic system

Strong limited rollout adoption across major hospital networks positions company for accelerated scale-up in interventional radiology


EU greenlights Dupixent for chronic urticaria, offering new hope to patients
Drug Approval | November 27, 2025

EU greenlights Dupixent for chronic urticaria, offering new hope to patients

It's a development that marks a major step forward for patients struggling with moderate-to-severe chronic spontaneous urticaria


Valent BioSciences opens new addition at Melnik and Shafer Biorational Research Center
News | May 30, 2024

Valent BioSciences opens new addition at Melnik and Shafer Biorational Research Center

Greg was also central to the planning, design, and construction of this facility


Dolomite Bio launches an affordable microfluidic system for custom protocol development
News | September 21, 2022

Dolomite Bio launches an affordable microfluidic system for custom protocol development

Dolomite Bio scientist demonstrating pipetting into the Nadia Go


Urinary incontinence 2nd biggest reason for limited mobility in elderly: Survey
News | July 26, 2022

Urinary incontinence 2nd biggest reason for limited mobility in elderly: Survey

72.5% elderly feel their generation used to spend more time with their elders, 52.4% feel lonely, shows PAN Health’s Liberty in Life of Older People 2022 survey


Pharma companies with ESG more valuable say investors
Sustainability | May 20, 2022

Pharma companies with ESG more valuable say investors

When asked how to balance ESG with broader business goals, the panel was unanimous in its assessment that ESG is ‘good for business’


Sanofi’s Dupixent pivotal trial meets all primary and secondary endpoints for treatment of atopic dermatitis
Biotech | August 31, 2021

Sanofi’s Dupixent pivotal trial meets all primary and secondary endpoints for treatment of atopic dermatitis

Results reinforce the well-established safety profile of Dupixent - the first-ever biologic medicine for atopic dermatitis currently approved for patients as young 6 years old